| | AUGUST 202419CIOReviewtherapy assets, most are genetically modified cell therapies for oncology indications, and only a minority are gene therapies in other major therapeutic areas (e.g., neurological, sensory, alimentary/metabolic). The scarcity of clinical-stage gene therapy assets is not just a temporary phenomenon. Rather, the transition of preclinical gene therapy assets into clinical stages turned out to be much harder due to safety concerns, manufacturing difficulties, and elevated complexities in clinical development. It's very important to recognize this transition bottleneck. Solutions have to be developed to break it in order to accelerate gene therapy drug development.What challenges in clinical development exacerbate this bottleneck?Among regulatory concerns toward gene therapy clinical studies, safety issues related to this new modality have been major factors slowing down clinical development for years. Currently, hepatoxicity is the most common and significant safety risk associated with AAV-based gene therapy. While gene therapies have been credited with saving thousands of lives, there have been a few severe hepatoxicity cases that resulted in several patients' deaths, such as with Zolgensma treatment for spinal muscular atrophy (SMA) and in Audentes/Astellas' AT132 gene therapy clinical trials for X-linked Myotubular Myopathy (XLMTM). Those incidents rightfully called for a thorough investigation. Careful monitoring should be enforced to minimize the safety risks in ongoing and future gene therapy clinical programs."The scarcity of clinical-stage gene therapy assets is not just a temporary phenomenon. Rather, the transition of preclinical gene therapy assets into clinical stages turned out to be much harder due to safety concerns, manufacturing difficulties, and elevated complexities in clinical development."Furthermore, the elevated complexity of gene therapy clinical development poses another major challenge. There are disease-related complexities, partly because most gene therapies so far are being developed for rare disease indications, and we have limited clinical knowledge and experience. The natural history of those rare diseases may not be well understood. In addition, diagnostic tools and/or diagnostic criteria are less well-defined. To make matters worse, clinical presentation varies greatly with the tiny but heterogeneous patient population. Some unique complexities are directly related to gene therapy, such as choices of administrative routes and immunogenicity. Finally, there are complexities related to clinical trial design and implementation, such as not well-established clinical endpoints, unreliable biomarkers, lack of clear controls to be used to demonstrate efficacy and safety, etc.More focused approachUnlike small molecule & biological, gene therapies primarily tackle a particular set of disease indications known to be caused by defective genes. Therefore, there is no need to screen a large number of drug candidates to select potentially effective treatments for any particular disease. Moreover, the technologies used to fit a piece of the correct gene onto a vector are similar across a large variety of disease indications. As a result, many gene therapy startup companies quickly developed platforms that produce many preclinical assets targeting various disease indications in a number of diverse therapeutic areas.However, once those preclinical gene therapy assets move into clinical stages, each asset requires a clinical team that is knowledgeable and experienced in the particular disease area. The platform approach that works so well at the preclinical stages is no longer usable at clinical stages; by underestimating the challenges of clinical development, gene therapy startups can be caught off-guard by the complexity of clinical development in diverse disease fields, realizing that their small clinical team can't cover multiple therapeutic areas and is destined for failure. Many are forced to consolidate their overly ambitious pipeline and instead focus on narrow therapeutic areas. Unlike small molecule & biological, gene therapies primarily tackle a particular set of disease indications known to be caused by defective genes
< Page 9 | Page 11 >